TY  - JOUR
AU  - Vijayaraghavan, Swetha
AU  - Maetzler, Walter
AU  - Reimold, Matthias
AU  - Lithner, Christina Unger
AU  - Liepelt-Scarfone, Inga
AU  - Berg, Daniela
AU  - Darreh-Shori, Taher
TI  - High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.
JO  - Alzheimer's and dementia
VL  - 10
IS  - 5
SN  - 1552-5260
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DZNE-2020-03856
SP  - 530-540.e1
PY  - 2014
AB  - Apolipoprotein E ε4 allele (APOE ε4) increases the apolipoprotein E (apoE) protein levels in Alzheimer's disease (AD) cerebrospinal fluid (CSF). Thus, we hypothesized that apoE levels were also associated with the APOE genotype, and amyloid-β (Aβ)-associated clinical, functional, and imaging parameters in patients with Lewy body-associated disorders (LBD). Indeed, similar to AD, patients with LBD displayed high CSF apoE levels (greatest in patients with dementia with LBD), and this was linked to APOE ε4. High CSF apoE protein correlated positively with CSF soluble amyloid precursor protein, total tau, and cortical and striatal Pittsburgh compound B retention; and correlated negatively with CSF Aβ42, cognitive tests scores, and glucose uptake ratio in the temporal and parietal cortices. APOE ε4-triggered accumulation of apoE in CSF is related to Aβ-associated clinical and functional imaging parameters in LBD. Accordingly, therapeutic strategies aimed at reducing apoE levels in the brain should be explored not only in AD but also in LBD, particularly when accompanied with dementia.
KW  - Aged
KW  - Aged, 80 and over
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Amyloid beta-Protein Precursor: cerebrospinal fluid
KW  - Aniline Compounds
KW  - Apolipoproteins E: cerebrospinal fluid
KW  - Apolipoproteins E: genetics
KW  - Biomarkers: cerebrospinal fluid
KW  - Brain: diagnostic imaging
KW  - Brain: metabolism
KW  - Brain: pathology
KW  - Carbon Radioisotopes
KW  - Cohort Studies
KW  - Female
KW  - Fluorodeoxyglucose F18
KW  - Glucose: metabolism
KW  - Humans
KW  - Lewy Body Disease: cerebrospinal fluid
KW  - Lewy Body Disease: diagnostic imaging
KW  - Lewy Body Disease: genetics
KW  - Lewy Body Disease: psychology
KW  - Male
KW  - Middle Aged
KW  - Neuropsychological Tests
KW  - Peptide Fragments: cerebrospinal fluid
KW  - Positron-Emission Tomography
KW  - Radiopharmaceuticals
KW  - Thiazoles
KW  - tau Proteins: cerebrospinal fluid
KW  - 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (NLM Chemicals)
KW  - APP protein, human (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Amyloid beta-Protein Precursor (NLM Chemicals)
KW  - Aniline Compounds (NLM Chemicals)
KW  - Apolipoproteins E (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Carbon Radioisotopes (NLM Chemicals)
KW  - MAPT protein, human (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
KW  - Radiopharmaceuticals (NLM Chemicals)
KW  - Thiazoles (NLM Chemicals)
KW  - amyloid beta-protein (1-42) (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
KW  - Fluorodeoxyglucose F18 (NLM Chemicals)
KW  - Glucose (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:23978325
DO  - DOI:10.1016/j.jalz.2013.03.010
UR  - https://pub.dzne.de/record/137534
ER  -